At this concentration, NSC107512 significantly enhanced 5-FU sensitivity (Fig. S8B), supporting the feasibility of pharmacological PUS7 inhibition as a strategy to potentiate 5-FU efficacy in CRC. This evidence concerns the gene PUS7 and colorectal carcinoma.